Document:

Exhibit 4.8

Exhibit 4.8

AMENDMENT NO. 1 TO THE SECOND AMENDED AND RESTATED 

REGISTRATION RIGHTS AGREEMENT

THIS AMENDMENT NO. 1 (this “Amendment”) TO THE SECOND AMENDED AND RESTATED
REGISTRATION RIGHTS AGREEMENT, dated as of March 26, 2010, is made and entered into by and among
VIA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and each of the parties
listed on Exhibit A hereto, as such Exhibit A may be amended from time to time
(collectively, the “Stockholders”). For the purposes of this Agreement, the term “Company”
shall be deemed to include and refer to any successor in interest to the Company, whether by means
of statutory conversion, merger, consolidation, recapitalization, reorganization or otherwise.

RECITALS

WHEREAS, certain of the Stockholders are parties to the Second Amended and Restated
Registration Rights Agreement, dated as of March 12, 2009 (the “Registration Rights
Agreement”), pursuant to which the Company has granted certain registration rights under the
Securities Act with respect to shares of Common Stock held by such Stockholders;

WHEREAS, the Company and certain Stockholders party hereto are entering into a Note and
Warrant Purchase Agreement (the “Purchase Agreement”) and Promissory Notes (the
“Promissory Notes”), each dated the date hereof, and as an inducement and partial
consideration for such Stockholders entering into such Purchase Agreement and Promissory Notes, the
Company is issuing to such Stockholders Warrants to Purchase Common Stock of VIA Pharmaceuticals,
Inc. (collectively, the “2010 Warrants”), dated as of the date hereof, pursuant to which
the Company is granting to such Stockholders the right to purchase from the Company an aggregate of
17,647,059 shares of Common Stock on the terms and conditions set forth in the 2010 Warrants;

WHEREAS, in accordance with the terms of the Purchase Agreement and the 2010 Warrants, the
Company desires to amend the Registration Rights Agreement to provide certain registration rights
to the Stockholders party to the 2010 Warrants with respect to the shares of Common Stock
underlying the 2010 Warrants;

WHEREAS, the provisions of the Registration Rights Agreement may be amended or waived at any
time by written agreement of the Company and the Stockholders of at least a majority of the
Registrable Common Stock (as defined in the Registration Rights Agreement); and

WHEREAS, the Company and the Stockholders of at least a majority of the Registrable Common
Stock (as defined in the Registration Rights Agreement) desire to amend the Registration Rights
Agreement to provide for such registration rights to the Stockholders with respect to the shares of
Common Stock underlying the 2010 Warrants.

 

 

 

NOW, THEREFORE, in consideration of the recitals and the mutual premises, covenants and
agreements herein contained and other good and valid consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties to this Amendment hereby agree as follows:

1. Amendment. The Registration Rights Agreement shall be amended as follows:

(a) The reference to the defined term “Warrants” as set forth in the Recitals to the
Registration Rights Agreement shall be replaced with a reference to “2009 Warrants”.

(b) The following definitions shall be added to Section 1 of the Registration Rights
Agreement:

“2010 Warrants” shall mean the warrants to purchase 17,647,059 shares of Common Stock
of the Company issued pursuant to each Warrant to Purchase Common Stock of VIA Pharmaceuticals,
Inc., as dated March 26, 2010.

“Warrants” shall mean both the 2009 Warrants and the 2010 Warrants.

(c) The definition of “Registrable Common Stock” in Section 1 of the Registration Rights
Agreement shall be deleted and replaced with the following:

“Registrable Common Stock” means at any time, any of the following owned by any
equity holder of the Company party to this Agreement: (i) Common Stock or other equity
securities of the Company in which the Common Stock then outstanding shall be reclassified
or changed, including by reason of a merger, consolidation, reorganization, recapitalization
or statutory conversion; (ii) Common Stock issuable upon exercise of any of the Warrants;
and (iii) any equity securities of the Company then outstanding which were issued as, or
were issued directly or indirectly upon the conversion, change or exercise of other equity
securities issued or issuable as a dividend, stock split, or other distribution with respect
or in replacement of any equity securities referred to in (i) or (ii) of this definition;
provided, however, that Registrable Common Stock shall not include any shares of Common
Stock (A) which have previously been registered or which have been sold to the public either
pursuant to a registration statement or Rule 144, or (B) which, in the opinion of counsel to
the Company, are eligible for resale by the Stockholder under Rule 144 without volume or
manner-of-sale restrictions.

2. Effective Time and Remainder of Agreement. This Amendment No. 1 to the Registration Rights
Agreement shall be effective as of the date hereof and, except as set forth herein, the
Registration Rights Agreement shall remain in full force and effect and shall be otherwise
unaffected hereby.

3. Miscellaneous.

(a) This Amendment and the rights and duties of the parties shall be governed by the laws of
the State of Delaware (without regard to conflicts of laws principles).

 

2

 

(b) This Amendment may be executed in any number of counterparts (including by facsimile) and
by different parties hereto in separate counterparts, with the same effect as if all parties had
signed the same document. All such counterparts shall be deemed an original, shall be construed
together and shall constitute one and the same instrument. This Amendment shall
become effective when each party hereto shall have received counterparts hereof signed by all
of the other parties hereto.

(c) The headings and other captions in this Amendment are for convenience and reference only
and shall not be used in interpreting, construing or enforcing any provision of this Amendment.

(d) If any term, provision, covenant or restriction of this Amendment is held by a court of
competent jurisdiction or other authority to be invalid, void or unenforceable, the remainder of
the terms, provisions, covenants and restrictions of this Amendment shall remain in full force and
effect and shall in no way be affected, impaired or invalidated so long as the economic or legal
substance of the transactions contemplated hereby is not affected in any manner materially adverse
to any party. Upon such a determination, the parties shall negotiate in good faith to modify this
Amendment so as to affect the original intent of the parties as closely as possible in an
acceptable manner in order that the transactions contemplated hereby be consummated as originally
contemplated to the fullest extent possible.

[Signature Pages Follow]

 

3

 

IN WITNESS WHEREOF, this Amendment No. 1 to the Second Amended and Restated Registration
Rights Agreement has been duly executed by each of the parties hereto as of the date first written
above.

	 	 	 	 	 
	VIA PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 
	By:

	 	/s/ Lawrence K. Cohen
 

Name: Lawrence K. Cohen
	 	 
	 

	 	Title: President and Chief Executive Officer	 	 

[Signature Page to Amendment No. 1 to the Second Amended and Restated Registration Rights Agreement]

 

 

 

	 	 	 	 	 
	BAY CITY CAPITAL FUND IV, L.P.	 	 
	 
	 	 	 	 
	By:

	 	Bay City Capital Management IV LLC	 	 
	Its:

	 	General Partner	 	 
	 
	 	 	 	 
	By:

	 	Bay City Capital LLC, its manager	 	 
	 
	 	 	 	 
	By:

	 	/s/ Fred Craves
 

Name: Fred Craves
	 	 
	 

	 	Title: Manager and Managing Director	 	 
	 
	 	 	 	 
	BAY CITY CAPITAL FUND IV	 	 
	CO-INVESTMENT FUND, L.P.	 	 
	 
	 	 	 	 
	By:

	 	Bay City Capital Management IV LLC	 	 
	Its:

	 	General Partner	 	 
	 
	 	 	 	 
	By:

	 	Bay City Capital LLC, its manager	 	 
	 
	 	 	 	 
	By:

	 	/s/ Fred Craves
 

Name: Fred Craves
	 	 
	 

	 	Title: Manager and Managing Director	 	 
	 
	 	 	 	 

[Signature Page to Amendment No. 1 to the Second Amended and Restated Registration Rights Agreement]

 

 

 

	 	 	 	 	 
	/s/ Lawrence K. Cohen	 	 
	 	 	 
	Lawrence Cohen	 	 
	 
	 	 	 	 

[Signature Page to Amendment No. 1 to the Second Amended and Restated Registration Rights Agreement]

 

 

 

Exhibit A

STOCKHOLDERS

Name/Address:

Bay City Capital Fund IV, L.P.

Bay City Capital Fund IV Co-Investment Fund, L.P.

     750 Battery Street

     Suite 400

     San Francisco, CA 94111

Thomas Quertermous

     810 Lathrop Drive

     Stanford, CA 94305

Adeoye Olukotun

     125 Hopewell-Wertsville Road

     Hopewell, NJ 08525

Douglass and Kim Given Revocable Trust

     133 Burns Avenue

     Atherton, CA 94027

Lawrence Cohen

     10065 Broadway Terrace

     Oakland, CA 94611

Raymond Tabibiazar

     2150 Sterling Avenue

     Menlo Park, CA 94025Exhibit 10.2

Exhibit 10.2

VIA PHARMACEUTICALS, INC.

NOTE AND WARRANT PURCHASE AGREEMENT

THIS NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”) is made as of March 26, 2010 by
and among VIA Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investors
listed on Schedule A hereto (each of which is herein referred to as an “Investor”).

THE PARTIES HEREBY AGREE AS FOLLOWS:

SECTION 1

ISSUANCE OF NOTES AND WARRANTS

1.1 Issuance of Notes. Subject to the terms and conditions of this Agreement, at the
Initial Closing (as defined below), the Company shall issue and sell to each Investor a promissory
note (each such note, as may be amended from time to time, a “Note” and collectively, the “Notes”)
in the form of Exhibit A attached hereto, in a principal amount (the “Principal Amount”) of
up to the amount set forth opposite such Investor’s name beneath the caption “Total Aggregate
Principal Amount” on Schedule A attached hereto. Each such Note shall be issued to such
Investor against payment by such Investor at the Initial Closing of the amount set forth opposite
such Investor’s name beneath the caption “Principal Amount of Initial Advance” on Schedule
A attached hereto. At each Subsequent Closing (as defined below), each Investor, to the extent
such Investor is participating in such Subsequent Closing, shall fund an additional advance to the
Company under such Investor’s Note and the grid attached as Schedule 1 to such Note shall be
updated to reflect such additional advance. Capitalized but otherwise undefined terms used herein
shall have the meanings provided therefor in the Notes.

1.2 Issuance of Warrants. Subject to the terms and conditions of this Agreement, at
the Initial Closing, the Company shall issue to each Investor a warrant (each such warrant, the
“Warrant” and collectively, the “Warrants”), in the form attached hereto as Exhibit B,
representing the right, subject to the terms of the Warrant, to purchase in the aggregate up to the
number of shares of Common Stock of the Company (as adjusted for stock splits, recapitalizations or
other similar events) set forth opposite such Investor’s name beneath the caption “No. of Warrant
Shares” on Schedule A attached hereto. Each Warrant shall, unless sooner terminated as
provided therein, have a term of five years from the date of the Initial Closing and shall be
exercisable (subject to the terms of the Warrant) at an exercise price (subject to adjustment as
set forth in the Warrant) equal to the Exercise Price.

1.3 Exercise Price. For purposes of this Agreement, “Exercise Price” shall mean $0.17
per share.

 

 

 

SECTION 2

CLOSINGS

2.1 Initial Closing. The initial closing of the purchase and sale of the Notes and
the Warrants hereunder (the “Initial Closing”) shall be held at Jones Day, 555 California Street,
San Francisco, California 94104 on the date of this Agreement or at such other place and date as is
mutually agreeable to the Company and the Investors.

2.2 Subsequent Closings. Subsequent to the Initial Closing, the Company may receive
additional advances from each Investor in accordance with the terms of each Note, up to a maximum
of the amount set forth opposite such Investor’s name beneath the caption “Total Aggregate
Principal Amount” (including the initial advance made at the Initial Closing). The closing of such
additional advances shall be held at Jones Day, 555 California Street, San Francisco, California
94104, on such date or at such other place as is mutually agreeable to the Company and the
Investors providing such additional advances (which each such date and place a “Subsequent Closing”
and, together with the Initial Closing, a “Closing”).

2.3 Conditions to Initial Closing. The several obligations of the Investors to
purchase the Notes on the date of the Initial Closing shall be subject to the prior or concurrent
satisfaction of each of the conditions precedent set forth in this Section 2.3.

(a) Security Agreements; Registration Rights Agreement. The Investors shall have
received, each executed and delivered by the Company and the Investors or any Collateral Agent on
their behalf (each, in form and substance satisfactory to the Investors): (i) a security agreement
(the “Security Agreement”) under which the Company grants to the Investors (or any Collateral Agent
on their behalf) a blanket security interest in its personal property; and (ii) a Collateral
Assignment of Patents (the “Patent Security Agreement”) under which the Company grants to the
Investors a security interest in all of the Company’s United States patents and applications for
United States patents. The Company’s existing Second Amended and Restated Registration Rights
Agreement, dated March 12, 2009 (the “Registration Rights Agreement”), shall be amended (in a form
satisfactory to the Investors in their sole discretion) such that the Company shall grant to the
Investors registration rights in respect of the Common Stock issuable upon exercise of the
Warrants.

(b) Resolutions, etc. The Investors shall have received (i) a certificate, dated the
date of the Initial Closing, of an authorized signatory of the Company as of the date of the
Initial Closing certifying (A) copies of the resolutions and other actions taken or adopted by the
Company authorizing the execution, delivery and performance of the Transaction Documents (as
defined below) to which the Company is a party (and confirming that no resolutions or actions
contrary to such resolutions or actions have been taken), and (B) the Certificate of Incorporation
of the Company (which shall also be certified by the Secretary of State of the state in which the
Company is organized or formed) and Bylaws of the Company, (ii) a good standing certificate with
respect to the Company as of a date recently prior to the date of the Initial Closing from the
Secretary of the State of the state in which the Company is organized or formed, and (iii) evidence
of qualification of the Company to do business in each jurisdiction where the nature of its
properties of the conduct of its business requires it to be so qualified to do business as of a

 

2

 

recent date and where the failure so to qualify could result in a Material Adverse Effect. As
used herein, the “Transaction Documents” means this Agreement, the Collateral Documents (as defined
below), the Notes, the Warrants, the Registration Rights Agreement (as amended hereby) and any
other and all other certificates, documents, agreements and instruments delivered to the Investors
under or in connection with this Agreement.  “Collateral Documents” means, collectively,
the Security Agreement, the Patent Security Agreement, and any other agreement pursuant to which
the Company or any other Person provides a Lien on its assets in favor of the Investors in
connection herewith, and all filings, documents and agreements made or delivered pursuant thereto.

(c) Collateral Matters. The Company shall have delivered to the Investors (or any
Collateral Agent on their behalf) each of the following: (i) confirmation that all UCC-1 financing
statements and other filings necessary or appropriate in the reasonable opinion of the Investors to
perfect the security interests of the Investors (or any Collateral Agent on their behalf) in the
Collateral have been accepted for filing; (ii) such lien and judgment searches as the Investors
have reasonably requested, and such termination statements or other documents, as may be necessary
to confirm that the Collateral is subject to no other security interests in favor of any Persons
other than Permitted Liens; (iii) the certificates or instruments representing any pledged
Collateral, together with undated stock powers or endorsements, as the case may be, executed in
blank, with respect thereto; (iv) if as of the date of the Initial Closing any Collateral is
located on any premises in which any third party has an interest, such bailee agreement,
subordination agreement, landlord waiver agreement or collateral access agreement, as applicable,
duly executed by such third party, as the Investors shall reasonably request; (v) evidence that all
other actions necessary or appropriate in the reasonable opinion of the Investors to perfect and
protect the security interests in the Collateral have been taken, including such account control
agreements in favor of the Investors (or any Collateral Agent on their behalf) with respect to the
Company’s deposit and securities accounts, executed by each applicable bank, broker or other
securities intermediary as the Investors shall reasonably request; and (vi) evidence of
satisfactory insurance coverage, together with evidence that the Investors have been named (or any
Collateral Agent on their behalf has been named) as loss payee under all policies of property
insurance and as additional insured under all policies of liability insurance.

(d) No Contest, etc. No claim, litigation, arbitration, governmental investigation,
injunction, order, proceeding or inquiry shall be pending or threatened which: (i) seeks to enjoin
or would be reasonably be expected to materially delay, impose material limitations on, or
otherwise prevent the consummation of, or to recover any damages or obtain relief as a result of,
the transactions contemplated by or in connection with the Transaction Documents; or (ii) would
otherwise be adverse to any of the parties hereto in any material respect with respect to the
transactions contemplated hereby.

(e) Certificate as to Completed Conditions, Warranties, No Default, etc. The
Investors shall have received a certificate, dated as of the date of the Initial Closing, of an
authorized signatory of the Company to the effect that: (i) all conditions precedent set forth in
this Section 2 have been satisfied; (ii) all representations and warranties set forth in
Section 4 are true and correct in all material respects (except for representations or
warranties already qualified by materiality, which shall be true and correct in all respects); and
(iii) all representations and warranties set forth in any other documents entered into in
connection herewith are true and
correct in all material respects (except for representations or warranties already qualified
by materiality, which shall be true and correct in all respects).

 

3

 

(f) Certificate as to Compliance with Requirements of Law. The Investors shall have
received a certificate, dated as of the date of the Initial Closing, of an authorized signatory of
the Company to the effect that the Company has obtained and maintains in full force and effect each
and every consent, approval, filing and registration by or with any Person, including, without
limitation, any Governmental Authority, necessary to authorize or permit the execution, delivery or
performance of the Transaction Documents, the issuance of the Notes and the Warrants (including any
approval, consent, filing and registration required under Federal or State securities laws), the
validity or enforceability thereof, or the consummation of the transactions contemplated by the
Transaction Documents.

(g) Due Diligence. The Investors shall have completed their business, legal, and
collateral due diligence with respect to the Company and shall be satisfied therewith.

2.4 Conditions to Subsequent Closings. Each Investor shall not have any obligation to
participate in any Subsequent Closing or otherwise to fund any amounts to the Company, other than
the obligation of such Investor in respect of the Initial Closing, subject to Section 2.3. Each
Investor may participate in any Subsequent Closing in its sole discretion. Prior and as a
condition to each Subsequent Closing, the Company shall deliver to the Investor participating in
such Subsequent Closing a certificate, dated as of the date of such Subsequent Closing, of an
authorized signatory of the Company confirming the matters set forth in Sections 2.3(e) and (f)
(with all representations and warranties so confirmed to be deemed made as of the date of such
Subsequent Closing). The Investor participating in any Subsequent Closing also may request, as a
condition to the closing of such Subsequent Closing, that the Company execute a Collateral
Assignment of Copyrights or a Collateral Assignment of Trademarks, each in the form attached as an
exhibit to the Security Agreement.

2.5 Delivery.

(a) Initial Closing. At the Initial Closing (i) each Investor shall deliver to the
Company a check or wire transfer of immediately available funds (pursuant to wire instructions
previously provided by the Company to the Investors) in the amount set forth opposite such
Investor’s name beneath the caption “Principal Amount of Initial Advance” on Schedule A
attached hereto, and (ii) the Company shall execute and deliver to each Investor a Note reflecting
the name of the Investor, the amount of the initial advance (which shall be set forth in the grid
attached as Schedule 1 to such Note), and the date of the Initial Closing, together with the
Investor’s Warrant as contemplated by Section 1.2.

(b) Subsequent Closings. At any Subsequent Closing, each Investor participating in
such Subsequent Closing shall deliver to the Company a check or wire transfer of immediately
available funds (pursuant to wire instructions previously provided by the Company to the Investors)
in the amount of such additional drawdown by the Company on such Note previously purchased by such
Investor, and such Investor shall provide the Company with a copy of the updated grid in Schedule 1
of the Note reflecting the additional drawdown made at such Subsequent Closing.

 

4

 

SECTION 3

REPRESENTATIONS AND WARRANTIES OF INVESTORS

Each Investor hereby represents and warrants to the Company that, as of the date of the
Initial Closing, and each Subsequent Closing at which such Investor participates:

3.1 Purchase for Own Account. Such Investor represents that it is acquiring the
Notes, the Warrants and the Common Stock issuable upon exercise of the Warrants (collectively, the
“Securities”) solely for investment for such Investor’s own account not as a nominee or agent, and
not with a view to the resale or distribution of any part thereof, and that such Investor has no
present intention of selling, granting any participation in, or otherwise distributing the same.
The acquisition by such Investor of any of the Securities shall constitute confirmation of the
representation by such Investor that such Investor does not have any contract, undertaking,
agreement or arrangement with any person to sell, transfer or grant participations to such person
or to any third person, with respect to any of the Securities.

3.2 Investment Experience. Either (i) such Investor or its officers, directors,
managers or controlling persons has a preexisting personal or business relationship with the
Company or its officers, directors or controlling persons, or (ii) such Investor, by reason of its
own business and financial experience, has the capacity to protect its own interests in connection
with the investment contemplated hereby. Such Investor represents that it is an investor in
securities of companies in the development stage and acknowledges that it is able to fend for
itself, can bear the economic risk of its investment, and has such knowledge and experience in
financial or business matters that it is capable of evaluating the merits and risks of the
investment in the Securities. Such Investor acknowledges that any investment in the Securities
involves a high degree of risk, and represents that it is able, without materially impairing its
financial condition, to hold the Securities for an indefinite period of time and to suffer a
complete loss of its investment.

3.3 Accredited Investor. Such Investor represents that it is an “accredited investor”
within the meaning of Securities and Exchange Commission (“SEC”) Rule 501 of Regulation D, as
presently in effect and, for the purpose of Section 25102(f) of the California Corporations Code,
it is excluded from the count of “purchasers” pursuant to Rule 260.102.13 thereunder.

3.4 Restrictions on Transfer. Such Investor understands that the Securities are
characterized as “restricted securities” under the federal securities laws inasmuch as they are
being acquired from the Company in a transaction not involving a public offering and that under
such laws and applicable regulations such securities may be resold without registration under the
Securities Act of 1933, as amended (the “Act”), only in certain limited circumstances. In this
connection, such Investor represents that it is familiar with SEC Rule 144, as presently in effect,
and understands the resale limitations imposed thereby and by the Act. SUCH INVESTOR UNDERSTANDS
AND ACKNOWLEDGES HEREIN THAT AN INVESTMENT IN THE COMPANY’S SECURITIES INVOLVES AN EXTREMELY HIGH
DEGREE OF RISK AND MAY RESULT IN A COMPLETE LOSS OF HIS, HER OR ITS INVESTMENT. Such Investor
understands that the Securities have not been and will not be registered under

 

5

 

 the Act (other than
as set forth in the Registration Rights Agreement) and have not been
and will not be registered or qualified in any state in which they are offered, and thus the Investor will not
be able to resell or otherwise transfer his, her or its Securities unless they are registered under
the Act and registered or qualified under applicable state securities laws, or an exemption from
such registration or qualification is available. Such Investor has no immediate need for liquidity
in connection with this investment and does not anticipate that it will need to sell his, her or
its Securities in the foreseeable future.

3.5 Further Limitations on Disposition. Without in any way limiting the
representations set forth above, such Investor further agrees not to make any disposition of all or
any portion of the Securities (other than the shares of Common Stock issuable on exercise of the
Warrants, during such time as a registration statement under the Act covering such shares is in
effect) unless and until the transferee has agreed in writing for the benefit of the Company to be
bound by this Section 3 and (i) such Investor shall have notified the Company of the proposed
disposition and shall have furnished the Company with a detailed statement of the circumstances
surrounding the proposed disposition, and (ii) if requested by the Company, such Investor shall
have furnished the Company with an opinion of counsel reasonably satisfactory to the Company that
such disposition will not require registration of such Securities under the Act. Notwithstanding
the foregoing provision, no such registration statement or opinion of counsel shall be necessary
for a transfer by such Investor that is a partnership or limited liability company to a partner of
such partnership or a member of such limited liability company or a retired partner of such
partnership who retires after the date hereof or a retired member of such limited liability company
who retires after the date hereof, or to the estate of any such partner, retired partner, member or
retired member or the transfer by gift, will or intestate succession by any partner or member to
his or her spouse or to the siblings, lineal descendants or ancestors of such partner or member or
his or her spouse, if the transferee agrees in writing to be subject to the terms hereof to the
same extent as if he or she were an original Investor hereunder.

3.6 Legends. The Investor understands that the Securities, and any securities issued
in respect thereof or exchange therefor, may bear one or all of the following legends:

(a) “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN
CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED
WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF
1933.”

(b) Any legend required by the Blue Sky laws of any state to the extent such laws are
applicable to the shares represented by the certificate so legended.

 

6

 

SECTION 4

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

The Company hereby represents and warrants to each Investor that, as of the date of the
Initial Closing and each Subsequent Closing and other than as disclosed in the Company’s public
filings:

4.1 Organization, Good Standing and Qualification; Licenses. The Company is duly
organized, validly existing and in good standing under the laws of the jurisdiction of its
organization and has all requisite power and authority, and holds all governmental licenses,
permits, registrations and other approvals required under applicable law, to own and hold under
lease its property and to carry on its business as now conducted and as proposed to be conducted,
except where the failure to hold any such licenses, permits, registrations and other approvals
could not result in a Material Adverse Effect. The Company is qualified to do business in each
jurisdiction where the nature of its properties of the conduct of its business requires it to be so
qualified to do business and where the failure so to qualify could result in a Material Adverse
Effect.

4.2 Authorization. All action on the part of the Company necessary for the
authorization, execution and delivery of this Agreement, the performance of all obligations of the
Company hereunder, and the authorization, issuance (or reservation for issuance), sale and delivery
of the Notes, the Warrants, and the shares of Common Stock underlying the Warrants, has been taken
or will be taken prior to each Closing. The Company covenants and agrees that all shares of Common
Stock which may be issued upon the exercise of the rights represented by the Warrants will, upon
issuance, be duly authorized, validly issued, fully paid and nonassessable and free from all
preemptive rights of any stockholder and free of all taxes, liens and charges with respect to the
issue thereof. The Company has reserved a sufficient number of shares of authorized but unissued
shares of Common Stock to provide for the exercise of the rights represented by the Warrants
(assuming full vesting thereof). Each of the Transaction Documents to which the Company is a party
constitutes the valid and legally binding obligation of the Company, enforceable against the
Company in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of
creditors’ rights generally, and (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies.

4.3 Litigation. There is no action, suit, proceeding or investigation pending or, to
the Company’s knowledge, currently threatened against the Company that questions the validity of
this Agreement, the right of the Company to enter into this Agreement, or to consummate the
transactions contemplated hereby, or that could reasonably be expected to result, either
individually or in the aggregate, in any Material Adverse Effect, nor is the Company aware that
there is any basis for the foregoing. The Company is not a party or subject to the provisions of
any order, writ, injunction, judgment or decree of any court or Governmental Authority. There is
no action, suit, proceeding or investigation by the Company currently pending or that the Company
intends to initiate.

 

7

 

4.4 Absence of Required Consents; No Violations. No consent, approval, order or
authorization of, or registration, qualification, designation, declaration or filing with, any
Governmental Authority on the part of the Company is required in connection with the consummation
of the transactions contemplated by the Transaction Documents, except for such filing(s) pursuant
to applicable state securities laws as may be necessary, which filings will be timely effected
after the relevant Closing, and except for recordings or filings in connection with the perfection
of the Liens on the Collateral in favor of the Investors (or any Collateral Agent on their behalf).
The Company is not in violation or default (i) of any provision of its Certificate of
Incorporation and Bylaws, or (ii) in any material respect of any instrument, judgment, order, writ,
decree or contract to which it is a party or by which it is bound, or, to the best of its
knowledge, of any provision of any federal or state statute, rule or regulation which is, to the
best of the Company’s knowledge, applicable to the Company (including the Employee Retirement
Income Security Act of 1974, as amended, and any Environmental Laws). The execution, delivery and
performance of the Transaction Documents and the consummation of the transactions contemplated
thereby will not result in any such violation or be in conflict with or constitute, with or without
the passage of time and giving of notice, either a default under any such provision, instrument,
judgment, order, writ, decree or contract or an event that results in the creation of any Lien upon
any material assets of the Company or the suspension, revocation, impairment, forfeiture or
nonrenewal of any material permit, license, authorization or approval applicable to the Company,
its business or operations or any of its assets or properties. As used herein, “Environmental
Laws” means all applicable federal, state and local laws, rules, regulations, codes, ordinances,
and the common law governing, regulating or otherwise affecting the environment or occupational
health and safety relating to exposures to Hazardous Materials, including the federal Clean Air
Act, the federal Clean Water Act, the federal Resource Conservation and Recovery Act, the federal
Comprehensive Environmental Response, Compensation and Liability Act, the federal Toxic Substances
Control Act and their state and local counterparts. The term “Hazardous Materials” means the
existence in any form of polychlorinated biphenyls, friable asbestos, urea formaldehyde foam
insulation, oil, gasoline, petroleum, petroleum products and petroleum-derived substances (other
than in vehicles operated in the ordinary course of business), pesticides and herbicides, and any
other chemical, material or substance deemed hazardous, toxic, corrosive, reactive, ignitable,
radioactive, or flammable under any Environmental Laws.

4.5 Transaction Documents. All representations and warranties of the Company
contained in the other Transaction Documents are true and correct in all material respects (except
for representations or warranties already qualified by materiality, which are true and correct in
all respects).

4.6 Insurance. All policies of insurance in effect of any kind or nature owned by or
issued to the Company, including policies of life, fire, theft, product liability, public
liability, property damage, other casualty, employee fidelity, workers’ compensation, property and
liability insurance, (a) are, together with all policies of employee health and welfare and title
insurance, if any, in full force and effect, (b) comply in all respects with the applicable
requirements set forth herein and (c) are of a nature and provide such coverage, including through
self-insurance, retentions and deductibles, as is customarily carried by companies engaged in
similar businesses and owning similar properties in the same general areas in which the Company
operates.

 

8

 

4.7 Permits. The Company has all franchises, permits, licenses, and any similar
authority necessary for the conduct of its business as now conducted and as presently proposed to
be conducted, the lack of which could materially and adversely affect the business, properties,
prospects, or financial condition of the Company. The Company is not in default in any material
respect under any of such franchises, permits, licenses, or other similar authority.

4.8 Intellectual Property. The Company has all intellectual property necessary for
the conduct of its business as now conducted and as presently proposed to be conducted, the lack of
which could materially and adversely affect the business, properties, prospects, or financial
condition of the Company. None of such intellectual property infringes on the rights of any other
person. The Company does not own any registered copyrights or registered trademarks. A complete
list of the Company’s United States patents and applications for United States patents is set forth
on Schedule A of the Patent Security Agreement.

4.9 Subsidiaries. The Company has no subsidiaries (direct or indirect) other than as
set forth in Exhibit 21.1 to its Annual Report on Form 10-K filed on March 27, 2009. Each direct
or indirect subsidiary of the Company (a) is not actively engaged in any business and (b) holds no
material assets.

4.10 Financial Statements. The Company has delivered to the Investors its unaudited
balance sheet, income statement and statement of stockholders’ equity at and for the three and nine
months ended September 30, 2009 (collectively, the “Financial Statements”). The Financial
Statements fairly present the financial condition and operating results of the Company as of the
dates, and for the periods, indicated therein, subject to normal year-end audit adjustments.
Except as set forth in the Financial Statements, and liabilities arising from the reduction of the
Company’s workforce pursuant to the plan adopted by the Company’s board of directors on March 26,
2010, the Company has no material liabilities (contingent or otherwise) other than (i) liabilities
incurred in the ordinary course of business subsequent to September 30, 2009, and (ii) obligations
under contracts and commitments incurred in the ordinary course of business and not required under
generally accepted accounting principles to be reflected in the Financial Statements, which, in
both cases, individually or in the aggregate, are not material to the financial condition or
operating results of the Company.

4.11 No Material Adverse Effect. Since the date of the Financial Statements, other
than as publicly disclosed by the Company in filings with the SEC, the reduction of the Company’s
workforce pursuant to the plan adopted by the Company’s board of directors on March 26, 2010 and
the failure of the Company to be able to repay existing indebtedness to the Investors when due, no
event has occurred or condition exists with respect to the Company or any other Person that has
resulted in, or could reasonably be expected to result in, a Material Adverse Effect.

4.12 Disclosure. None of the representations or warranties made by the Company herein
as of the date of such representations and warranties, and none of the statements contained in any
other information with respect to the Company and its properties and assets, including each exhibit
or report, furnished by or on behalf of the Company to the Investors in connection herewith,
contains any untrue statement of a material fact or omits any material fact required to
be stated therein or necessary to make the statements made therein, in the light of the
circumstances under which they are made, not misleading.

 

9

 

4.13 Offering. Subject in part to the truth and accuracy of each Investor’s
representations set forth in Section 3 of this Agreement, the offer, sale and issuance of
the Notes and the Warrants as contemplated by this Agreement are exempt from the registration
requirements of the Act and will not result in a violation of the qualification or registration
requirements of the any applicable state securities laws, and neither the Company nor any
authorized agent acting on its behalf will take any action hereafter that would cause the loss of
such exemption.

SECTION 5

MISCELLANEOUS

5.1 Survival of Representations, Warranties and Covenants. The warranties,
representations and covenants of the Company and the Investors contained in or made pursuant to
this Agreement shall survive the execution and delivery of this Agreement and all Closings and
shall in no way be affected by any investigation of the subject matter thereof made by or on behalf
of the Investors or the Company.

5.2 Successors and Assigns. Except as otherwise provided therein, the terms and
conditions of this Agreement and the other Transaction Documents shall inure to the benefit of and
be binding upon the respective successors and assigns of the parties (including transferees of any
Securities); provided, however, that the Company may not assign or transfer its
rights or obligations hereunder or under the other Transaction Documents without the prior written
consent of all Investors. Nothing in this Agreement, express or implied, is intended to confer
upon any party other than the parties hereto or their respective successors and assigns any rights,
remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement.

5.3 Governing Law; Jury Trial Waiver. This Agreement is to be construed in accordance
with and governed by the laws of the State of California. The Company irrevocably waives, to the
fullest extent permitted by law, any objection which it may now or hereafter have to the laying of
the venue of any such proceeding brought in such a court and any claim that any such proceeding
brought in such a court has been brought in an inconvenient forum. Nothing herein shall affect the
right of any Investor to bring proceedings against the Company in the courts of any other
jurisdiction. EACH OF THE INVESTORS AND THE COMPANY HEREBY KNOWINGLY, VOLUNTARILY, AND
INTENTIONALLY WAIVE ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED
HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS AGREEMENT OR ANY OTHER TRANSACTION
DOCUMENT. THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE INVESTORS ENTERING INTO THIS AGREEMENT.

 

10

 

5.4 Counterparts. This Agreement may be executed in several counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

5.5 Titles and Subtitles. The titles and subtitles used in this Agreement are used
for convenience only and are not to be considered in construing or interpreting this Agreement.

5.6 Notices. Except as may be otherwise provided herein, all notices, requests,
waivers and other communications made pursuant to this Agreement shall be in writing and shall be
conclusively deemed to have been duly given (a) when hand delivered to the other party; (b) when
sent by facsimile or electronic mail to the number or electronic mail address set forth on the
signature pages hereto if sent between 8:00 a.m. and 5:00 p.m. recipient’s local time on a Business
Day, or on the next Business Day if sent by facsimile or electronic mail to the number or
electronic mail address set forth on the signature pages hereto if sent other than between 8:00
a.m. and 5:00 p.m. recipient’s local time on a Business Day; (c) three Business Days after deposit
in the U.S. mail with first class or certified mail receipt requested postage prepaid and addressed
to the other party at the address set forth on the signature pages hereto; or (d) the next Business
Day after deposit with a national overnight delivery service, postage prepaid, addressed to the
parties as set forth on the signature pages hereto with next Business Day delivery guaranteed,
provided that the sending party receives a confirmation of delivery from the delivery service
provider. Each Person making a communication hereunder by facsimile or electronic mail shall
promptly confirm by telephone to the Person to whom such communication was addressed each
communication made by it by facsimile or electronic mail pursuant hereto but the absence of such
confirmation shall not affect the validity of any such communication. A party may change or
supplement the addresses given above, or designate additional addresses, for purposes of this
Section 5.6 by giving the other party written notice of the new address in the manner set forth
above.

5.7 Finder’s Fee. Each party represents that it neither is nor will be obligated for
any finder’s fee or commission in connection with this transaction. Each Investor agrees to
indemnify and to hold harmless the Company from any liability for any commission or compensation in
the nature of a finder’s fee (and the costs and expenses of defending against such liability
or asserted liability) for which each Investor or any of its officers, employees, or
representatives is responsible. The Company agrees to indemnify and hold harmless each Investor
from any liability for any commission or compensation in the nature of a finder’s fee (and the
costs and expenses of defending against such liability or asserted liability) for which the Company
or any of its officers, employees or representatives is responsible.

5.8 Amendments and Waivers. Any term of this Agreement may be amended and the
observance of any term of this Agreement may be waived (either generally or in a particular
instance and either retroactively or prospectively), only if such amendment, modification or waiver
is in writing and only with the written consent of the Company and all Investors. Any amendment or
waiver effected in accordance with this section shall be binding upon each holder of any Securities
acquired under this Agreement at the time outstanding, each future holder of all such Securities,
and the Company.

 

11

 

5.9 Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, such provision shall be excluded from this Agreement and the
balance of the Agreement shall be interpreted as if such provision were so excluded and shall be
enforceable in accordance with its terms.

5.10 Corporate Securities Law. THE SALE OF THE SECURITIES THAT ARE THE SUBJECT OF
THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF
CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE
CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS
EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE.
THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING
OBTAINED, UNLESS THE SALE IS SO EXEMPT.

5.11 Expenses. The Company shall reimburse the reasonable expenses of the Investors
(including the fees of one special counsel for both of the Investors) with respect to the
negotiation, execution and delivery of this Agreement and the other Transaction Documents, in an
amount not to exceed $35,000 in the aggregate.

5.12 Register. The Company shall maintain at its principal executive offices a
register for the Securities, in which the Company shall record the name and address of the person
in whose name the Securities have been issued (including the name and address of each transferee)
and the amount of the Securities held by such person. The Company shall keep the register open and
available during business hours for inspection by the Investors or their legal representatives upon
prior written notice.

5.13 Interpretation. In this Agreement and the other Transaction Documents, except to
the extent the context otherwise requires: (i) any reference in this Agreement or other
Transaction Document to a Section, a Schedule or an Exhibit is a reference to a Section thereof, a
schedule thereto or an exhibit thereto, respectively, and to a subsection thereof or a clause
thereof is, unless otherwise stated, a reference to a subsection or a clause of the Section or
subsection in which the reference appears; (ii) the words “hereof,” “herein,” “hereto,” “hereunder”
and the like mean and refer to this Agreement or other Transaction Document as a whole and not
merely to the specific Section, subsection, paragraph or clause in which the respective word
appears; (iii) the meaning of defined terms shall be equally applicable to both the singular and
plural forms of the terms defined; (iv) references to agreements and other contractual instruments
shall be deemed to include all subsequent amendments and other modifications thereto;
(v) references to statutes or regulations are to be construed as including all statutory and
regulatory provisions consolidating, amending or replacing the statute or regulation referred to;
and (vi) the captions and headings are for convenience of reference only and shall not affect the
construction of this Agreement or other Transaction Document.

 

12

 

5.14 Further Assurances. Each party agrees to cooperate fully with the other parties
and to execute such further instruments, documents and agreements and to give such further written
assurance as may be reasonably requested by any other party to evidence and reflect the
transactions described in this Agreement and the other Transaction Documents and contemplated
hereby and thereby and to carry into effect the intents and purposes of this Agreement and the
other Transaction Documents.

5.15 Entire Agreement. This Agreement and the documents referred to herein constitute
the entire agreement among the parties with respect to the subject matter hereof and no party shall
be liable or bound to any other party in any manner by any warranties, representations or covenants
except as specifically set forth herein or therein.

* * *

 

13

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	COMPANY:

VIA PHARMACEUTICALS, INC.

 	 
	 	By:  	/s/ Lawrence K. Cohen
 	 
	 	 	Name:  	Lawrence K. Cohen 	 
	 	 	Title:  	President and Chief Executive Officer 	 
	 
	 	Address:

VIA Pharmaceuticals, Inc.

750 Battery Street, Suite 330

San Francisco, California 94111

Attention: Chief Financial Officer

Facsimile: (415) 283-2201

Electronic mail: James.Stewart@viapharmaceuticals.com

 	 

[Signature page to Note and Warrant Purchase Agreement]

 

14

 

	 	 	 	 	 
	 	INVESTORS:

BAY CITY CAPITAL FUND IV, L.P.

 	 
	 	By:  	Bay City Capital Management IV LLC, its general partner
 	 
	 	 	 
	 	By:  	Bay City Capital LLC, its manager
 	 
	 	 	 
	 	By:  	/s/ Fred Craves
 	 
	 	 	Name:  	Fred Craves 	 
	 	 	Title:  	Managing Director and Manager 	 
	 
	 	Address:

Bay City Capital Fund IV, L.P.

750 Battery Street, Suite 400

San Francisco, California 94111

Attention: Managing Director

Facsimile: (415) 835-5569

Electronic mail: lionel@baycitycapital.com

 	 
	 	BAY CITY CAPITAL FUND IV CO-INVESTMENT FUND, L.P.,

 	 
	 	By:  	Bay City Capital Management IV LLC, its general partner
 	 
	 	 	 
	 	By:  	 Bay City Capital LLC, its manager
 	 
	 	 	 
	 	By:  	/s/ Fred Craves
 	 
	 	 	Name:  	Fred Craves 	 
	 	 	Title:  	Managing Director and Manager 	 
	 
	 	Address:

Bay City Capital Fund IV, L.P.

750 Battery Street, Suite 400

San Francisco, California 94111

Attention: Managing Director

Facsimile: (415) 835-5569

Electronic mail: lionel@baycitycapital.com

 	 

[Signature page to Note and Warrant Purchase Agreement]

 

15

 

SCHEDULE A

SCHEDULE OF INVESTORS

Closing Dated March 29, 2010

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Principal	 	 	Total Aggregate	 	 	No. of	 
	 	 	Amount	 	 	Principal	 	 	Warrant	 
	Name	 	of Initial Advance	 	 	Amount	 	 	Shares	 
	Bay City Capital Fund IV, L.P.
	 	$	1,223,625	 	 	$	2,936,700	 	 	 	17,274,706	 
	 
	Bay City Capital Fund IV
Co-Investment Fund, L.P.
	 	$	26,375	 	 	$	63,300	 	 	 	372,353	 
	 
	 	 	 	 	 	 	 	 	 
	 
	TOTAL
	 	$	1,250,000	 	 	$	3,000,000	 	 	 	17,647,059	 

 

 

 

EXHIBIT A

FORM OF PROMISSORY NOTE

 

 

 

EXHIBIT B

FORM OF WARRANT TO PURCHASE COMMON STOCK

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]